We've updated our Privacy Policy to make it clearer how we use your personal data. We use cookies to provide you with a better experience. You can read our Cookie Policy here.

Advertisement
Evotec Logo

Evotec

Evotec are a R&D biotech that offers accelerating, high value pipeline co-creation partnerships and comprehensive CRO/CDMO services – always striving for highest quality, capital efficient execution of R&D programs from disease understanding towards IND, Phase 1, and beyond. Our expertise spans across therapeutic/disease areas and most modalities, especially small molecules and biotherapeutics. We take pride in acting as "drug hunters" in deep collaboration with our partners to advance science. At the core of our operations are our industrialized, AI-powered proprietary R&D platforms, including PanOmics and iPSC technologies. These platforms are instrumental in enhancing disease understanding and ensuring human relevance in our research. By integrating AI and continuous manufacturing technology, we facilitate better access to high-quality biotherapeutics, revolutionizing the way treatments are developed and produced.

Latest Content

Researchers conducting a clinical trial in a laboratory using pipettes and test tubes.
Product News

Evotec-Partner Bayer Starts Phase 2 Study for Alport Syndrome

Bayer launches Phase 2 study of Evotec-partnered antibody BAY 3401016 for Alport syndrome kidney disease.
Gloved hands holding a vial with a depiction of DNA strands inside and on the background.
Product
Advertisement

Oligonucleotide Solutions from Target ID and Validation to IND

Explore the path from target ID to IND for oligonucleotide therapeutics, featuring Ionis CEO Brett Monia, insights on RNA-targeted innovation, and expert guidance for developing groundbreaking oligo therapies.
The cover of the Accelerating Oligonucleotide Therapeutics ebook on a blue background
eBook

Transforming Drug Discovery With Oligonucleotide Therapeutics

Despite their potential, oligonucleotide programs often face hurdles in delivery, toxicity and off-target effects. This eBook explores critical aspects of oligonucleotide development, from in silico design to regulatory support.
Digital illustration of damaged neurons representing neurodegeneration in the brain.
Product News

Evotec Announces Progress in Preclinical Neuroscience Partnership With Bristol Myers Squibb

Evotec secured a $25M payment from Bristol Myers Squibb for progress in their joint neurodegenerative disease pipeline.
3D illustration of an immune cell interacting with a target cell, representing autoimmune and inflammatory disease research
Poster

Uncovering Novel Drug Targets for Autoimmune and Inflammatory Diseases

This poster explores how a robust CRISPR-based screening platform enables the identification of novel regulators of the Treg phenotype to support drug discovery.
Digital illustration of a brain formed by DNA strands representing precision and personalized medicine.
Webinar

Insights Into the Acute Central Nervous System Responses to Oligonucleotide Delivery

On-Demand
Join this webinar to explore how these insights can improve assessment of safety and tolerability in oligonucleotide-based therapies targeting the CNS.
Digital illustration of a human figure with DNA strands representing multiomics data integration.
Article

Designing the Future of Multiomics Research

The article highlights how large-scale and longitudinal studies, wearables and national data initiatives are advancing multiomics research to improve disease prediction and prevention.
A hand holding a blood sample in a test tube with a red cap, showing a distinct separation of yellow and red liquids.
Whitepaper

Achieve Exceptional Longitudinal Performance in Clinical Plasma Proteomics

This whitepaper shows how an industrialized MS platform delivers <5% median precision across protein groups and sustained reproducibility for FDA-approved biomarkers over nearly a year of plasma analysis.
Abstract blue background with molecular structures and digital lines representing proteomics research.
Webinar

Unlocking High-Value Targets: The Power of Chemoproteomics and Covalent Mass Spectrometry

On-Demand
Join this webinar to discover how integrating these complementary approaches can reduce off-target risks, accelerate timelines and improve confidence in progressing from hit to lead – helping researchers strengthen their discovery pipeline.
Evotec brochure highlighting the Molecular Patient Database E.MPD for advancing precision medicine with integrated multi-omics data
eBook

Advance Precision Medicine Through Integrated Multi-Omics Patient Data

This eBook demonstrates how integrated multi-omics patient databases revolutionize precision medicine by combining molecular data with clinical insights to accelerate therapeutic discovery and enable personalized treatments.

Advertisement